Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

What Next For Medtech And Investors Post-Coronavirus? (<em>In Vivo</em>)

What Next For Medtech And Investors Post-Coronavirus? (In Vivo)

Related Content

Preparing for EDGAR Next – New Requirements for All EDGAR Filers

FDA Publishes Its First Draft Guidance On Use of Artificial Intelligence in the Development of Drugs and Biological Products

FDA Approves Celltrion’s AVTOZMA (tocilizumab-anoh)

FDA Publishes Its First Draft Guidance On Use of Artificial Intelligence in the Development of Drugs and Biological Products

Amgen and Celltrion Settle Denosumab BPCIA Case

Alvotech and Teva Announce Acceptance of BLA for AVT05, a Golimumab Biosimilar

FDA Publishes Its First Draft Guidance On Use of Artificial Intelligence in the Development of Drugs and Biological Products

Teva Announces New Biosimilar Deals

Goodwin Rare Disease Symposium 2025

Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Goodwin Advised Aclarion on the $4.7 Million Closing of Registered Direct Offering of Common Stock

Goodwin Expands Antitrust Litigation Offering with the Arrival of Partner Alexandra Russell in Washington, D.C.

Goodwin Advises Underwriters in Metsera’s $275 Million Initial Public Offering

Goodwin Advises Royalty Pharma on $511 Million Sale of Morphosys Development Funding Bonds

Goodwin Advises GENFIT on Non-Dilutive Royalty Financing Agreement for up to €185 Million

Goodwin Continues to Lead the 2024 M&A and Private Equity League Tables

Life Sciences

Technology

Medtech